ArticleJAMA psychiatry2018
Association of Hippocampal Atrophy With Duration of Untreated Psychosis and Molecular Biomarkers During Initial Antipsychotic Treatment of First-Episode Psychosis.
Article in JAMA psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advancing study of cognitive impairments for antipsychotic-naïve psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology.Schizophrenia research · 2020Pooled it
- Hippocampal Subfield Volumes Predict Disengagement from Maintenance Treatment in First Episode Schizophrenia.Schizophrenia bulletin · 2023Trial
- The ventral/anterior hippocampus as a central hub for stress-related dopaminergic circuit dysfunction in psychiatric disorders.Molecular psychiatry · 2026Review
- Development and validation of a model for predicting relapse in patients with first-episode schizophrenia.BMC psychiatry · 2026Article
- From Micro Molecular to Functional Levels Through Macro Structures: Mediation of Structural Brain Changes on the Relationship Between Oxidative Stress and Cognition in Early Onset Psychosis.Schizophrenia bulletin open · 2026Article
- Easy-to-use and easy-to-interpret quality control of 3D gradient echo T1-weighted MR acquisition sequences for improved test-retest stability of MRI-based hippocampus volumetry.Journal of Alzheimer's disease : JAD · 2025Article
- The Pathobiological Underpinnings of Psychosis: From the Stress-Related Hypothesis to a Multisystemic Approach.NeuroSci · 2025Review
- Medications for psychosis in people with schizophrenia: what happens if you take them and what happens if you don't?CNS spectrums · 2025Review
- Development and validation of the help-seeking motivation scale for patients with schizophrenia(HSMS).BMC psychiatry · 2025Article
- Functional and structural alterations in different durations of untreated illness in the frontal and parietal lobe in major depressive disorder.European archives of psychiatry and clinical neuroscience · 2024Article
- Review of Major Social Determinants of Health in Schizophrenia-Spectrum Psychotic Disorders: III. Biology.Schizophrenia bulletin · 2023Article
- Oxidative stress impairs cognitive function by affecting hippocampal fimbria volume in drug-naïve, first-episode schizophrenia.Frontiers in neuroscience · 2023Article
- The neurobiology of duration of untreated psychosis: a comprehensive review.Molecular psychiatry · 2023Review
- Vascular-related biomarkers in psychosis: a systematic review and meta-analysis.Frontiers in psychiatry · 2023Review
- Correlation between duration of untreated psychosis and long-term prognosis in chronic schizophrenia.Frontiers in psychiatry · 2023Article
- Coupling Between Hippocampal Parenchymal Fraction and Cortical Grey Matter Atrophy at Different Stages of Cognitive Decline.Journal of Alzheimer's disease : JAD · 2023Article
- Peripheral Blood Levels of Brain-Derived Neurotrophic Factor in Patients with First Episode Psychosis: A Systematic Review and Meta-Analysis.Brain sciences · 2022Review
- Inflammatory Subtypes in Antipsychotic-Naïve First-Episode Schizophrenia are Associated with Altered Brain Morphology and Topological Organization.Brain, behavior, and immunity · 2022Article
- Multivariate relationships between peripheral inflammatory marker subtypes and cognitive and brain structural measures in psychosis.Molecular psychiatry · 2021Article
- Effect of citalopram on hippocampal volume in first-episode schizophrenia: Structural MRI results from the DECIFER trial.Psychiatry research. Neuroimaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Importance: Duration of untreated psychosis (DUP) has been associated with poor outcomes in schizophrenia, but the mechanism responsible for this association is not known. Objectives: To determine whether hippocampal volume loss occurs during the initial 8 weeks of antipsychotic treatment and whether it is associated with DUP, and to examine molecular biomarkers in association with hippocampal volume loss and DUP. Design, Setting, and Participants: A naturalistic longitudinal study with matched healthy controls was conducted at Shanghai Mental Health Center. Between March 5, 2013, and October 8, 2014, 71 medication-naive individuals with nonaffective first-episode psychosis (FEP) and 73 age- and sex-matched healthy controls were recruited. After approximately 8 weeks, 31 participants with FEP and 32 controls were reassessed. Exposures: The participants with FEP were treated according to standard clinical practice with second-generation antipsychotics. Main Outcomes and Measures: Hippocampal volumetric integrity (HVI) (an automated estimate of the parenchymal fraction in a standardized hippocampal volume of interest), DUP, 13 peripheral molecular biomarkers, and 14 single-nucleotide polymorphisms from 12 candidate genes were determined. Results: The full sample consisted of 71 individuals with FEP (39 women and 32 men; mean [SD] age, 25.2 [7.7] years) and 73 healthy controls (40 women and 33 men; mean [SD] age, 23.9 [6.4] years). Baseline median left HVI was lower in the FEP group (n = 57) compared with the controls (n = 54) (0.9275 vs 0.9512; difference in point estimate, -0.020 [95% CI, -0.029 to -0.010]; P = .001). During approximately 8 weeks of antipsychotic treatment, left HVI decreased in 24 participants with FEP at a median annualized rate of -.03791 (-4.1% annualized change from baseline) compared with an increase of 0.00115 (0.13% annualized change from baseline) in 31 controls (difference in point estimate, -0.0424 [95% CI, -0.0707 to -0.0164]; P = .001). The change in left HVI was inversely associated with DUP (r = -0.61; P = .002). Similar results were found for right HVI, although the association between change in right HVI and DUP did not achieve statistical significance (r = -0.35; P = .10). Exploratory analyses restricted to the left HVI revealed an association between left HVI and markers of inflammation, oxidative stress, brain-derived neurotrophic factor, glial injury, and markers reflecting dopaminergic and glutamatergic transmission. Conclusions and Relevance: An association between longer DUP and accelerated hippocampal atrophy during initial treatment suggests that psychosis may have persistent, possibly deleterious, effects on brain structure. Additional studies are needed to replicate these exploratory findings of molecular mechanisms by which untreated psychosis may affect hippocampal volume and to determine whether these effects account for the known association between longer DUP and poor outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.